On 2 July, 2015, Alere signed an agreement to sell its BBI business to Exponent Private Collateral LLP, a UK-based personal equity company, for a total purchase price of around $164 million, based on forex rates on that time, including up to $47 million in contingent concern. The ultimate purchase price is subject to an operating capital adjustment. BBI Group provides products and services for the diagnostic, health care, research, defense and meals industries globally. Related StoriesConfocal microscope designed designed for scientists launched by Caliber IDEfficient respiratory diagnosis solutionRapid, award winning diagnostic testing to be provided at MEDICAThe close of the BBI sale is definitely subject to regulatory approvals, including applicable anti-trust authorization, approvals by CFIUS and from the Directorate of Protection Trade Settings of the U.S.Related StoriesViralytics enters into scientific trial collaboration agreement with MSDOvarian cancer individuals with a brief history of oral contraceptive use have better outcomesCornell biomedical engineers develop 'very natural killer cells' to destroy cancers cells in lymph nodesThe Screening Issues campaigns aims to clear up any confusion about cancers screening and raise the amount of people participating in screening. With an increase of people attending screening more cancer deaths shall be prevented. Professor Stephen Duffy, Malignancy Study UK’s professor of screening, said: ‘The uncertainty around what is screened for could possibly be from a variety of reasons.